Results 31 to 40 of about 13,011 (272)

How early can myocardial iron overload occur in Beta thalassemia major? [PDF]

, 2014
BACKGROUND: Myocardial siderosis is the most common cause of death in patients with beta thalassemia major(TM). This study aimed at investigating the occurrence, prevalence and severity of cardiac iron overload in a young Chinese population with beta TM.
A Aessopos, AM Maceira, AW Leung, B Modell, B Modell, B Modell, BA Davis, C Borgna-Pignatti, DH Fitchett, DJ Weatherall, DT Kremastinos, F Alpendurada, G Barosi, Gaohui Yang, GM Brittenham, GM Brittenham, HF Pan, Hongfei Pan, JC Wood, JC Wood, JC Wood, JL Fernandes, K Tziomalos, Liling Long, Lisa Anderson, LJ Anderson, LJ Anderson, M Angastiniotis, M Bejaoui, M Westwood, MA Aldouri, MA Tanner, MA Tanner, MA Tanner, MAEM Engle, NF Olivieri, P Kirk, Peng Peng, Q Meng, Rongrong Liu, Shaohong Tan, T He, Taigang He, V Positano, Weijia Yang, Xiaolei Xu, Xingjiang Long, Xinhua Zhang, Yong-rong Lai, Yongrong Lai   +49 more
core   +2 more sources

Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia

Cancer Medicine, 2019
Deferasirox is an oral iron‐chelating agent having possible antileukemia and immune modulatory effects. Few reports have evaluated deferasirox in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the impact of
Byung‐Sik Cho, Young‐Woo Jeon, A‐Reum Hahn, Tai‐Hyang Lee, Sung‐Soo Park, Jae‐Ho Yoon, Sung‐Eun Lee, Ki‐Seong Eom, Yoo‐Jin Kim, Seok Lee, Chang‐Ki Min, Seok‐Goo Cho, Jong‐Wook Lee, Woo‐Sung Min, Hee‐Je Kim   +14 more
doaj   +1 more source

Genetic polymorphisms influencing deferasirox pharmacokinetics, efficacy, and adverse drug reactions: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Objective: Deferasirox is an iron-chelating agent prescribed to patients with iron overload. Due to the interindividual variability of deferasirox responses reported in various populations, this study aims to determine the genetic polymorphisms that ...
Kittika Yampayon, Puree Anantachoti, Bunchai Chongmelaxme, Varalee Yodsurang, Varalee Yodsurang   +4 more
doaj   +1 more source

The potential of deferasirox as a novel therapeutic modality in gastric cancer [PDF]

, 2016
Background: Iron is a crucial element for cell proliferation, growth, and metabolism. However, excess iron and altered iron metabolism are both associated with tumor initiation and tumor growth. Deferasirox is an oral iron chelator. Although some studies
���������
core   +1 more source

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation [PDF]

, 2014
This is the first prospective study of deferasirox in adult allogeneic hematopoietic stem cell transplant recipients with transfusional iron overload in hematologic malignancies.
Cantarero Vallejo, Montserrat Batlle, Lourdes Vázquez, C. Solano, Antònia Sampol, Rafael F. Duarte, Dolores Hernández‐Maraver, Joaquín Martínez‐López, M Rovira, Santiago Jiménez, David Valcárcel, V. Belloch, Moraima Jiménez, I. Jarque   +13 more
openalex   +4 more sources

Invasive fungal infections secondary to traumatic injury [PDF]

, 2017
Invasive fungal infection (IFI) is a rare but serious complication of traumatic injury. The purpose of this article is to review the epidemiology, natural history, mycology, risk factors, diagnosis, treatment, and outcomes associated with post-traumatic ...
Bochicchio, Grant, Bochicchio, Kelly, Kronen, Ryan, Liang, Stephen Y, Powderly, William G, Spec, Andrej   +5 more
core   +3 more sources

Impact of iron chelation with deferasirox on telomere length and oxidative stress in hemodialysis patients: A randomized study

Nefrología (English Edition)
Background: Recent studies have demonstrated the effectiveness, safety, and tolerability of deferasirox in patients in peritoneal dialysis, however, its effect has not been studied in patients undergoing hemodialysis. Objective: To investigate the impact
Blanca Olivia Murillo Ortiz, Joel Ramírez Emiliano, Marcos Javier Romero Vázquez, Lauro Fabián Amador Medina, Sandra Martínez Garza, Edna Montserrat Ramos Rodríguez   +5 more
doaj   +3 more sources

Synthesis and Characterization of Deferasirox PLGA Nanoparticles and Investigation of Toxicity in Cell Model

Journal of Mazandaran University of Medical Sciences, 2022
Background and purpose: Cancer is one of the causes of mortality worldwide. Evidence suggests that iron depletion by a chelator agent suppresses the development of some cancer cells. Deferasirox is shown to have anticancer properties.
Hamidreza Mohammadi, Javad Akhtari, Sara Assadpour, Mitra Kamali, Pedram Ebrahimnejad   +4 more
doaj  

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

Haematologica, 2011
Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and ...
Alessia Pepe, Antonella Meloni, Marcello Capra, Paolo Cianciulli, Luciano Prossomariti, Cristina Malaventura, Maria Caterina Putti, Alma Lippi, Maria Antonietta Romeo, Maria Grazia Bisconte, Aldo Filosa, Vincenzo Caruso, Antonella Quarta, Lorella Pitrolo, Massimiliano Missere, Massimo Midiri, Giuseppe Rossi, Vincenzo Positano, Massimo Lombardi, Aurelio Maggio   +19 more
doaj   +1 more source

Desensibilización a deferasirox en una paciente con hemocromatosis. Reporte de un caso

Revista Alergia México, 2023
Antecedentes: Deferasirox es un quelante de hierro activo, indicado en el tratamiento de pacientes con hemocromatosis; sin embargo, se ha informado que el 28% de los casos puede tener reacciones adversas al fármaco. El protocolo de desensibilización para
Nadia Karina Aguilar Hinojosa, Evelyn Itzamara Figueroa Saavedra   +1 more
doaj   +1 more source